1250T Clavulanic Acid Expansion

1250T Clavulanic Acid Expansion Project

Established in 1973, the GSK Irvine site is a world leader in the primary manufacture of antibiotics. 330 people work at Irvine with plant operations running on a continuous 24 hour schedule every day of the year.

The strategic role of the Irvine site is to be a secure, competitive supplier of 6-APA and Potassium Clavulanate to support GSK's anti-infectives franchises and the needs of external customers and patients.

To support the increased market demand for Augmenten, of which Potassium Clavulanate is a key primary ingredient, G&T is working with GSK to increase the manufacturing capacity of the plant from 900t/year to 1250t/year. This will mean substantial increases to the existing building cubic capacity and appropriate additional process equipment and utilities.




Irvine, Scotland

View all projects on map

Next Project

Stevenage Bioscience Catalyst Phases 1&2

View Project
Copy the URL below and share: